OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 317 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR When He Said His Mother-In-Law Was Going To Live In The... March 6, 2019 Breast Cancer Survivor Driven from Her Home by Noxious Gases from... June 11, 2021 First-of-its-kind app for patients on clinical trials being piloted by Cancer... November 28, 2022 pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... February 16, 2021 Load more HOT NEWS Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... Five Questions With…Desiree. Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts
